CASE REPORT

Facklamia hominis pyelonephritis in a pediatric patient: first case report and review of the literature

Samantha Pérez-Cavazos1, Daniela Cisneros-Saldaña1, Fernando Espinosa-Villaseñor1, José Iván Castillo-Bejarano1, Denisse Natalie Vaquera-Aparicio1, Hugo Sánchez-Alanís2, and Abiel Mascareñas-De los Santos1*

Abstract

Background: Pyelonephritis is one of the most serious bacterial illnesses during childhood. Gram-negative organisms account for up to 90% of the cases. Gram-positive bacteria are uncommon causes of urinary tract infections, and only a few cases caused by Facklamia hominis have been reported in the literature.

Case presentation: A five-year-old girl with tracheostomy and gastrostomy and past medical history of congenital lymphangioma presented with a two-week history of intermittent fever, frequent urination, and vesical tenesmus. Diagnosis of pyelonephritis was made. Urine culture reported colonies with alpha-hemolysis in blood agar at 48-h of incubation and Facklamia hominis was identified by MALDI-TOF. The patient was successfully treated with gentamicin.

Conclusions: This is the first reported case of pyelonephritis by Facklamia hominis in a child, and the second involving infection in a pediatric patient. Although this pathogen is uncommon, current treatment of F. hominis is a challenge for physicians. This case illustrates the requirement to standardize identification and treatment of care to avoid treatment failure and antimicrobial resistance.

Keywords: Facklamia hominis, Urinary tract infection, Emerging pathogen, Child, Children, Pediatric

Background

Acute pyelonephritis is an infection that affects renal parenchyma and in children, it represents one of the most common causes of serious bacterial illnesses. 80–90% of cases are caused by Escherichia coli, and the remaining 10–20% by other Gram-negative bacilli, such as Klebsiella, Enterobacter, Proteus, and Pseudomonas species, and certain Gram-positive organisms such as Enterococcus faecalis, Staphylococcus saprophyticus, and Streptococcus agalactiae [1, 2].

Facklamia species are rarely involved in human infections. These Gram-negative cocci are alfa-hemolytic, catalase negative, and facultatively anaerobic [3–7]. From six members of this genus, only four (F. hominis, F. sourekii, F. ignava, and F. languida) have been identified in human clinical specimens, causing a range of illnesses such as sepsis, bacteremia, abscesses, peritonitis, meningitis, endocarditis, genitourinary infection, chorioamnionitis, and prosthetic joint infection [3–6]. Facklamia hominis is the most common member of this genus involved in human infection [3]. We present the first reported case of pyelonephritis caused by Facklamia hominis in a child.
Case presentation

We present the case of a 5-year-old girl from Mexico, with a medical history of a congenital cervical lymphangioma, with a partial surgical resection during the neonatal period, requiring a gastrostomy and tracheostomy, and currently being treated with oral sirolimus (0.8 mg/m² twice a day). She presented to the emergency department with a two-week history of intermittent fever, increased urination frequency, and vesical tenesmus, for which she was treated in an out-patient clinic with levofloxacin for seven days with no clinical response. Upon physical examination she had mild abdominal tenderness and left costovertebral angle tenderness. Complete blood count (CBC) was normal (leukocytes 6.25 k/µL, neutrophils 3.1 k/µL, lymphocytes 2.3 k/µL, hemoglobin 12.6 g/dL, and platelets 249,000/mm3). Acute phase reactants were slightly elevated (C-reactive protein 1.1 mg/dL, erythrocyte sedimentation rate 30 mm/h). Urinalysis was normal (negative nitrites, leukocyte esterase, and no leukocytes). Renal ultrasound showed a normal right kidney, and echogenic bands in the superior pole of the left kidney, in addition to renal sinus compression, and areas of cortical hypoperfusion in color-Doppler examination, suggestive of focal left pyelonephritis (Fig. 1). Blood and urine cultures were taken upon admission, the latter obtained via vesical catheterization. Given that the patient had no history of recent hospitalization, intravenous gentamicin (6 mg/kg/day) was empirically initiated as a second line

![Renal ultrasonography images: showing evidence of focal left pyelonephritis. A Echogenic bands in superior pole of left kidney with compression of the renal sinus. B Diminished perfusion in the superior pole of left kidney in color-Doppler ultrasound](image-url)
of treatment for community-acquired pyelonephritis. Blood cultures were negative. After a 48-h incubation period, urine culture reported growth of colonies with alpha-hemolysis on blood agar (>100,000 CFU/mL) (Fig. 2). Colonies were identified as *Facklamia hominis* by a MALDI-TOF Biotyper® using a matrix-assisted laser desorption/ionization and time-of-flight (MALDI-TOF) mass spectrometry system, with a score value of 2.03. Antimicrobial susceptibility was determined via disc method, and the four antibiotics tested (vancomycin, gentamicin, tetracycline, linezolid) were susceptible. Quinolones were not available in laboratory. The patient presented clinical resolution of symptoms within 72 h of therapy. Due to the rarity of the case, a follow-up urine culture was performed 14-day later, with no growth reported, and she was discharged after completing a two week-course of gentamicin.

**Discussion and conclusions**

The genus *Facklamia* was first described in 1997 by Collins et al., using comparative 16S recombinant ribonucleic acid (rRNA) gene sequencing studies, and it currently comprises six species: *F. ignava*, *F. sourekii*, *F. tabaciasalis*, *F. languida*, *F. miroungii* and *F. hominis* [4, 6, 8]. Only *F. tabaciasalis* and *F. miroungii* have not been isolated from human specimens [3, 8]. Recently, a novel species, *Facklamia lactis* sp. nov. was isolated from a German bulk tank milk [9].

The natural habitat of *Facklamia* species remains unknown, however strains associated to human infection seem to be rare members of commensal microbiota of skin, and the female genitourinary tract [8]. *Facklamia* species are uncommon human pathogens, and since the description of the genus, very few cases of *Facklamia* spp human infections have been reported in medical literature [3, 7, 10]. The pathogenic potential and virulence of this genus is yet to be elucidated [7].

*F. hominis* has been isolated from several clinical specimens such as urine, vagina, blood, abscesses, synovial fluid, mitral valves, placenta, gastric aspirates, cerebrospinal fluid, and preputial swabs [6–8, 10–14].

In this case, our patient presented with pyelonephritis and inadequate clinical response to initial treatment with quinolones. Normal findings in CBC and the moderate elevation in acute phase reactants could be explained either by the immunosuppressive properties of sirolimus, or due to a partial response to levofloxacin. However, therapy failure cannot be adjudicated to resistance to levofloxacin, as its susceptibility was not tested in the urine isolate due to routine laboratory protocols. In this case it could not be determined if *F. hominis* was part of the vaginal microbiota of the child, as vaginal cultures were not performed upon admission or after treatment, nonetheless follow-up urine cultures were negative.

The role of sirolimus or other immunosuppressive agents in the pathogenicity of *Facklamia* infections is unknown. Sirolimus has been associated with a higher rate of mucosal herpes simplex virus infections, however that association has not been observed with other pathogens such as cytomegalovirus and hepatitis C; also it has been documented to have antifungal-activity in vitro, as it inhibits the growth of some species such as *Cryptococcus neoformans*, *Candida albicans* and *Aspergillus fumigatus* [15].

We performed a literature search in four languages (spanish, english, german and korean) of core databases including MEDLINE (National Library of Medicine, Bethesda, MD), SciELO (Scientific Electronic Library Online), Google Scholar (Palo Alto, California) and Web of Science (Clarivate Analytics, Philadelphia, Pennsylvania), between 1990 and 2021 using the keywords: “*Facklamia* spp”, “*Facklamia* species” “*F. hominis*”, “*F. languida*”, “*F. ignava*”, “*F. sourekii*”, “*F. miroungii*” and “*F. tabaciasalis*” to identify case reports and case series. References of the selected publications were reviewed to recognize duplicate reports on case series. References of the selected publications were reviewed to recognize duplicate reports on case series. Twelve cases of infections due to *F. hominis* were identified. A summary of demographic and clinical data, including risk factors and treatment is available in Table 1.

*Facklamia* species are Gram-positive, catalase-negative, facultative anaerobic cocci, and its identification with traditional microbiologic tests can represent a challenge. Depending on species and growth conditions, they
can be found in pairs, clusters, or chains, and on sheep blood agar colonies are non-pigmented and weakly alpha-hemolytic or non-hemolytic. Due to its resemblance in Gram-stain characteristics, colony morphology, hemolysis on 5% sheep blood agar, and catalase reaction, they may be misidentified as viridans-group Streptococci or discarded as contaminants [3, 7, 8, 10].

*Facklamia* species can be recognized by their production of leucine aminopeptidase (LAP), L-pyrrolidonyl-beta-naphthylamide (PYR), and their ability to grow in 6.5% sodium chloride containing media [3–7].

Species of *Facklamia* have been identified using the API Rapid ID32 STREP system, API ZYM method, Vitek® 2 system (bioMerieux France), matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF), and DNA sequence coding for 16S RNA [6, 8, 14] In the present case, *Facklamia hominis* was successfully identified by MALDI-TOF.

The distinction of *Facklamia* spp from viridans-group Streptococci and other *Streptococcus*-like organisms is clinically relevant because of its unusual susceptibility pattern. Susceptibility testing has been defined using the Clinical and Laboratory Standards Institute Guidelines for *Streptococcus* species other than *Streptococcus pneumoniae*. Physicians must be aware of the several limitations concerning *Facklamia* infections, as to date there is no standardized method of identification, or treatment guidelines available, and taking into account the inconsistency of susceptibility profiles reported, clinical decisions should be taken considering the susceptibility pattern of the isolate in question [7, 8].

### Table 1  Summary of *Facklamia hominis* infection risk factors, diagnostic methods, and treatment

| Pub year/Place | Gender/Age | Underlying condition | Infection | Sample | Identification Method | Provided antibiotic treatment |
|----------------|------------|----------------------|-----------|--------|-----------------------|-------------------------------|
| 2004, UK [10] | F/ 34 Y    | Pregnancy            | Chorioamnionitis and puerperal bacteremia | Placental tissue swabs and placental tissue | ND | Amoxicillin and clavulanic acid Metronidazole |
| 2010, UK [11] | ND/ ND     | Ischemic stroke      | Endocarditis | Blood culture | PCR | Gentamicin and Vancomycin |
| 2012, India [12] | M/ 35 Y  | Rheumatic heart disease | Endocarditis | Blood culture | Vitek®2 system | Ceftriaxone Gentamicin |
| 2014, Spain [5] | F/ 81 Y   | Obesity              | Prosthetic joint infection | Periprosthetic femoral Prosthetic tissue, femoral interface membrane, acetabular interface membrane | Vitek®2 system | Amoxicillin Ceftriaxone |
| 2015, France [16] | F/40 Y    | None                 | Scapular abscess | Abscess culture | MALDI-TOF | Pristinamycine |
| 2015, USA [13] | F/41 Y    | Recurrent sinusitis  | Meningitis | CSF culture | Vitek®2 system | Ceftriaxone |
| 2017, Germany [17] | M/63 Y   | Melanoma             | Thoracic abscess | Abscess culture | PCR | Clindamycin |
| 2019, Spain [18] | M/9 Y     | Phimosis + balano-preputial adhesions | Balanoposthitis | Urethral exudate culture | MALDI-TOF | Amoxicillin and clavulanic acid |
| 2019, Korea [19] | M/67 Y    | Hepatitis B virus-cirrhosis | Epidermal cyst | Wound secretion culture | Vitek®2 system | Amoxicillin and clavulanic acid |
| 2020, Switzerland [14] | M/75 Y   | Benign prostatic hyperplasia + transurethral prostate resection | Urosepsis | Urine culture | RAST (vClassic RAST) | Ampicillin-Sulbactam Vancomycin |
| 2020, France [6] | F/ 57 Y   | Uterine myomatosis and obesity | Peritonitis | Peritoneal culture | MALDI-TOF Vitek MS® | Cefotaxime Metronidazole Amoxicillin |
| 2021, USA [20] | F/64 Y    | Type 2 diabetes melitus and coronary artery disease | Hidradenitis suppurativa | Axillary abscess culture | MALDI-TOF | Moxifloxacin Vancomycin Trimethoprim/Sul-famethoxazole |
| 2021, Mexico | F/ 7 Y    | Congenital lymphangiomatous | Pyelonephritis | Urine culture | MALDI-TOF | Gentamicin |

* M male, F female, CFS cerebrospinal fluid, PCR polymerase chain reaction, MALDI-TOF matrix-assisted laser desorption/ionization time-of-flight, ND no data
Outcomes of *F. hominis* infections are mostly encouraging when appropriate antibiotic therapy is warranted, such as the case we present [6].

**Conclusion**

This case is the second reported in a pediatric patient, the first reported in Latin America, and the first case of *Facklamia hominis* pyelonephritis in a child. Although this pathogen is an uncommon cause of infection, its identification and treatment remain a challenge for physicians. A variety of antibiotics have been used, including penicillin and third generation cephalosporins. In our case, the patient was successfully treated with gentamicin. Overall, our attestations point up that *F. hominis* is responsible of a variety of human infections and should be considered as an emerging pathogen, however there is scarce information of its virulence and pathogenic potential. This case illustrates the importance of appropriately identifying the bacteria and its susceptibility patterns, to prevent treatment failure and to avoid selective pressure on microbiota, thus preventing antimicrobial resistance.

**Abbreviations**

API: Analytical Profile Index; CBC: Complete blood count; CFU: Colony-forming unit; DNA: Deoxyribonucleic acid; LAP: Leucine aminopeptidase; MALDI-TOF: Matrix-assisted laser desorption/ionization time-of-flight; PYR: L-pyrrolidonyl-beta-naphthylamide; RNA: Ribonucleic acid.

**Acknowledgements**

Thanks to the Radiology Department, Microbiology Department and Bacteriology Laboratory of Hospital Universitario “José Eleuterio González” for their special contribution.

**Authors’ contributions**

JJC-B & DN-A: coordination; SP-C & DC-S: analysis and writing; AM-DS: conception and coordination; FF-V: design of the work; HS-A: identification in laboratory. All authors read and approved the final manuscript.

**Funding**

This research did not receive any specific Grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Availability of data and materials**

Not applicable.

**Declarations**

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Written informed consent for publication of clinical details and clinical images was obtained from the parents of the patient. A copy of the consent form is available for review by the editor of the journal.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1. Department of Pediatrics / Infectious Diseases Service, Hospital Universitario “Dr. José Eleuterio González” Universidad Autónoma de Nuevo León, Francisco I. Madero Avenue, Mitras Centro, ZC 64460 Monterrey, Mexico. 2. Department of Clinical Pathology, Hospital Universitario “Dr. José Eleuterio González” Universidad Autónoma de Nuevo León, Francisco I. Madero Avenue, Mitras Centro, ZC 64460 Monterrey, Mexico.

**References**

1. Kline KA, Lewis AL. Gram-positive uropathogens, polymicrobial urinary tract infection, and the emerging microbiota of the urinary tract. Microbiol Spectr. 2016;4:2. https://doi.org/10.1128/microbiolspec.UIT-0012-2012.

2. Morello W, La Scola C, Alberici I, Montini G. Acute pyelonephritis in children. Pediatr Nephrol. 2016;31(8):1253–65.

3. Mostafa HH, Taftner SM, Wang J, Malek A, Hardy DJ, Pecora ND. Genome sequence of a facklamia hominis isolate from a patient with urosepsis. Microbiol Resour Announc. 2019;8(17):e00100‑e119.

4. Collins MD, Felsen E, Lemozy J, Akervall E, Sjödén B, Lawson PAY. Notes: phenotypic and phylogenetic characterization of some globicella-like organisms from human sources: description of Facklamia hominis gen nov, sp nov. Int J Syst Evol Microbiol. 1997;47(3):880–2.

5. Corona PS, Haddad S, Andrés J, González‑López JJ, Amat C, Flores X. Case report: first report of a prosthetic joint infection caused by Facklamia hominis. Diagn Microbiol Infect Dis. 2014;80(4):338–40.

6. Ait Tamliah Y, Violette J, Labrousse J, Biegeaud D, Vincent J. Identification of Facklamia hominis in a Case of Stercoral Peritonitis: A Case Report and Review of the Literature. Infect Dis. 2020;4:138.

7. Rahmati E, Martin V, Wong D, Sattler F, Petterson J, Ward P, et al. Facklamia Species as an Underrecognized Pathogen. Open Forum Infectious Dis‑e2017. 2017:4:1. https://doi.org/10.1093/ofid/ofv272.

8. Hoyles L. The genus Facklamia. In: Lactic Acid Bacteria. John Wiley & Sons, Ltd, 2014. p. 91–8. https://onlinelibrary.wiley.com/doi/abs/10.1002/9781118655252.ch8

9. Doll EV, Staub L, Huptas C, Scherer S, Wenning M. Facklamia lactis sp. nov, isolated from raw milk. Int J Syst Evol Microbiol. 2021;71(7):004869.

10. Healy B, Beukenholt RW, Tuthill D, Ribeiro CD. Facklamia hominis causing chorioamnionitis and puerperal bacteraemia. J Infect. 2005;50(4):353–5.

11. Safavi S, Tufnell M, Bhalla A. Multi‑territory ischaemic strokes and sub‑cute bacterial endocarditis. BMJ Case Rep. 2010;2010:bcr0620092023.

12. Ananthakrishna R, Shankarappa RK, Jagadeesan N, Math RS, Karur S, Nanjappa MC. Infective endocarditis: a rare organism in an uncommon setting. Case Rep Infect Dis. 2012;2012:307852.

13. Parvataneni KC, Iyer S, Khabib R, Saravolatz LD. Facklamia Species and Strepotoccus pneumoniae meningitis: a case report and review of the literature. Open Forum Infect Dis. 2015;2:2. https://doi.org/10.1093/ofid/ofv039.

14. Gahl M, Stockl T, Fahmer R. Facklamia hominis bacteraemia after transure‑thral resection of the prostate: a case report. BMC Urol. 2020;20(2):192.

15. Husain S, Singh N. The impact of novel immunosuppressive agents on infections in organ transplant recipients and the interactions of these agents with antimicrobials. Clin Infect Dis. 2002;35(1):53–61.

16. Abat C, Garcia V, Rolain J‑M. Facklamia hominis scapula abscess, Marseille, France. New Microbes New Infections. 2016;32:278–80.

17. Schlipköter M, Grieser T, Forst H. Unusual complication following placement of an epidural catheter: Anaesthesist. 2017;66(7):506–10.

18. Goméz‑Luque JM, Foronda‑García‑Hidalgo C, Gutiérrez‑Fernández J. Balanopostitis por Facklamia hominis en Pediatría. Rev Esp Quimioter. 2019;32(3):13–4.

19. Kim TY, Jo J, Kim M, Park H, Roh EY, Yoon JH, et al. Facklamia hominis Isolated from a Wound: A Case Report and Review of the Literature. Infect Dis. 2020;4:138.

20. Basal Y, Oommen J, Faraj U, Acho R, Aravapally A. Facklamia hominis in hidradenitis suppurativa. JAAD Case Rep. 2021;7:20–2.